HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Sangamo Therapeutics, maintaining a $5 price target.
October 23, 2024 | 9:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Sangamo Therapeutics, maintaining a $5 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Sangamo Therapeutics' future performance. This could lead to a short-term positive impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100